Standard BioTools

Standard BioTools Receivables/Revenue

The Receivables to Revenue Ratio of Standard BioTools (LAB) as of Nov 5, 2026 is 18.49 %. In the previous year, Receivables to Revenue Ratio was 17.66 % — a change of 4.67% (higher).

Receivables/Revenue

18.49 %

YoY

4.67%

Last updated:

Receivables to Revenue Ratio of Standard BioTools is 2023 18.49 % . Receivables to Revenue Ratio of Standard BioTools was 2022 17.66 % . It decreases by 4.67% higher compared to the previous year.

The Standard BioTools Receivables/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables/Revenue
Date
Receivables/Revenue
Jan 1, 2016
13.98 USD
Jan 1, 2017
14.71 USD
Jan 1, 2018
14.78 USD
Jan 1, 2019
16.21 USD
Jan 1, 2020
18.39 USD
Jan 1, 2021
14.01 USD
Jan 1, 2022
17.66 USD
Jan 1, 2023
18.49 USD
The Standard BioTools Receivables/Revenue history
YEARReceivables/RevenueYoY
18.49 %+4.67%
17.66 %+26.03%
14.01 %-23.78%
18.39 %+13.46%
16.21 %+9.62%
14.78 %+0.47%
14.71 %+5.27%
13.98 %-37.12%
22.23 %+15.57%
19.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Receivables to Revenue Ratio of Standard BioTools is 18.49 % in 2023.

Receivables to Revenue Ratio of Standard BioTools changed from 17.66 % to 18.49 %, representing a 4.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Receivables to Revenue Ratio Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

The Receivables/Revenue ratio shows what percentage of annual revenue is tied up in accounts receivable. Rising ratios may signal collection issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Receivables to Revenue Ratio's Standard BioTools with sector peers and the industry average to assess whether it is attractive.

To evaluate Receivables to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Receivables to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Standard BioTools

All Key Metrics — Standard BioTools